Sotera Health (NASDAQ:SHC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sotera Health (NASDAQ:SHC) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of analysts recently issued reports on SHC shares. Barclays increased their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Citigroup increased their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a report on Tuesday, August 6th.

Insider Buying and Selling at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

Institutional investors have recently modified their holdings of the company. William Blair Investment Management LLC increased its position in shares of Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after purchasing an additional 6,707 shares during the last quarter. Clearline Capital LP bought a new position in shares of Sotera Health during the 2nd quarter valued at about $1,707,000. First Pacific Advisors LP bought a new position in shares of Sotera Health during the 2nd quarter valued at about $540,000. Darsana Capital Partners LP bought a new position in shares of Sotera Health during the 2nd quarter valued at about $29,074,000. Finally, Bank of New York Mellon Corp increased its position in shares of Sotera Health by 3.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,004,046 shares of the company’s stock valued at $11,918,000 after purchasing an additional 37,681 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Stock Down 1.4 %

Shares of NASDAQ SHC opened at $15.32 on Thursday. The business’s fifty day moving average price is $16.00 and its 200-day moving average price is $13.83. The stock has a market capitalization of $4.34 billion, a PE ratio of 61.28 and a beta of 2.08. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a one year low of $10.71 and a one year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the company posted $0.18 EPS. On average, equities research analysts anticipate that Sotera Health will post 0.61 EPS for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.